Acelyrin (SLRN) and Alumis (ALMS) reaffirmed Tuesday their commitment to merge in an all-stock transaction, as Acelyrin said its board had determined that Concentra Biosciences' unsolicited indication of interest is "not reasonably expected to result in a superior proposal."
Acelyrin and Alumis said their combined company would have a pro forma cash position of about $737 million, which is expected to fund operating expenses and capital expenditure requirements into 2027.
Separately, Acelyrin said its board is confident that the Alumis deal would maximize long-term value for its stockholders.
The companies said they continue to expect their merger to close in Q2, subject to approval by the stockholders of both companies and other customary closing conditions.
Acelyrin shares were down more than 8% in recent trading while Alumis shares were up 0.4%.
Price: 2.46, Change: -0.23, Percent Change: -8.55
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。